Summary
With more than 13 million people dying per year from infectious diseases Multidrug Resistance (MDR) in bacteria remains the
greatest challenge in public health care. This scenario, associated to the low turnover of new clinically approved antibiotic
drugs makes the development of innovative therapeutic approaches to fight antibiotic resistance desperately needed to
address this devastating societal problem. In this frame, SUPREME aims at the implementation of a novel strategy based
on unprecedented supramolecular platforms based on new cyclodextrin polymers integrating light-activatable nitric oxide (NO)
photodonors (NOPD), alone and in combination with antibiotics currently employed in the clinic. The final goal is to exploit
the double role of NO generated with superb spatiotemporal control thanks to the light triggering, as: i)
bactericidal species not suffering MDR when produced at high doses (micro molar); ii) inhibitor of the efflux pumps mainly responsible
for MDR, when produced at low doses, to revert antibiotic resistance. Highly biocompatible branched polymers containing mixed (alpha, beta and gamma) cyclodextrin units will be used as suitable hosts able to self-assemble into nanoparticles or gels
encapsulating the therapeutic cargo with high efficiency. We will focus on NOPDs activatable exclusively with the
biocompatible visible light and on antibiotics representative of the classes of fluoroquinolones and
tetracyclines, known to display resistance and severe side effects. Full chemico-physical and photochemical characterization
of the systems is planned as well as assessment of their efficacy against planktonic microbial cells and biofilms. The complementary
expertise of the researcher and the supervisor supported by the private and academic teams hosting the fellow during
secondments will create a multidisciplinary environment where all participants will benefit from reciprocal transfer of
knowledge.
greatest challenge in public health care. This scenario, associated to the low turnover of new clinically approved antibiotic
drugs makes the development of innovative therapeutic approaches to fight antibiotic resistance desperately needed to
address this devastating societal problem. In this frame, SUPREME aims at the implementation of a novel strategy based
on unprecedented supramolecular platforms based on new cyclodextrin polymers integrating light-activatable nitric oxide (NO)
photodonors (NOPD), alone and in combination with antibiotics currently employed in the clinic. The final goal is to exploit
the double role of NO generated with superb spatiotemporal control thanks to the light triggering, as: i)
bactericidal species not suffering MDR when produced at high doses (micro molar); ii) inhibitor of the efflux pumps mainly responsible
for MDR, when produced at low doses, to revert antibiotic resistance. Highly biocompatible branched polymers containing mixed (alpha, beta and gamma) cyclodextrin units will be used as suitable hosts able to self-assemble into nanoparticles or gels
encapsulating the therapeutic cargo with high efficiency. We will focus on NOPDs activatable exclusively with the
biocompatible visible light and on antibiotics representative of the classes of fluoroquinolones and
tetracyclines, known to display resistance and severe side effects. Full chemico-physical and photochemical characterization
of the systems is planned as well as assessment of their efficacy against planktonic microbial cells and biofilms. The complementary
expertise of the researcher and the supervisor supported by the private and academic teams hosting the fellow during
secondments will create a multidisciplinary environment where all participants will benefit from reciprocal transfer of
knowledge.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101057562 |
| Start date: | 01-08-2022 |
| End date: | 30-11-2024 |
| Total budget - Public funding: | - 172 750,00 Euro |
Cordis data
Original description
With more than 13 million people dying per year from infectious diseases Multidrug Resistance (MDR) in bacteria remains thegreatest challenge in public health care. This scenario, associated to the low turnover of new clinically approved antibiotic
drugs makes the development of innovative therapeutic approaches to fight antibiotic resistance desperately needed to
address this devastating societal problem. In this frame, SUPREME aims at the implementation of a novel strategy based
on unprecedented supramolecular platforms based on new cyclodextrin polymers integrating light-activatable nitric oxide (NO)
photodonors (NOPD), alone and in combination with antibiotics currently employed in the clinic. The final goal is to exploit
the double role of NO generated with superb spatiotemporal control thanks to the light triggering, as: i)
bactericidal species not suffering MDR when produced at high doses (micro molar); ii) inhibitor of the efflux pumps mainly responsible
for MDR, when produced at low doses, to revert antibiotic resistance. Highly biocompatible branched polymers containing mixed (alpha, beta and gamma) cyclodextrin units will be used as suitable hosts able to self-assemble into nanoparticles or gels
encapsulating the therapeutic cargo with high efficiency. We will focus on NOPDs activatable exclusively with the
biocompatible visible light and on antibiotics representative of the classes of fluoroquinolones and
tetracyclines, known to display resistance and severe side effects. Full chemico-physical and photochemical characterization
of the systems is planned as well as assessment of their efficacy against planktonic microbial cells and biofilms. The complementary
expertise of the researcher and the supervisor supported by the private and academic teams hosting the fellow during
secondments will create a multidisciplinary environment where all participants will benefit from reciprocal transfer of
knowledge.
Status
SIGNEDCall topic
HORIZON-MSCA-2021-PF-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
